Skip to main content

Immunic, Inc 8-K, filed Nov 13, 2026

Immunic, Inc. (IMUX)

8-K 2026-11-13 For: 2026-11-13
View Original
Added on November 13, 2026

About this 8-K

Immunic, Inc filed this 8-K on November 13, 2026.

Immunic said fully enrolled Phase 3 ENSURE-1 and ENSURE-2 trials remain on track for December 2026 top-line data; third-quarter net loss was approximately $42.3 million, and $132.0 million cash is expected to fund operations into late 2027. AI summary

Items reported

  • Item 2.02: Financial results
  • Item 9.01: Financial statements and exhibits